Clinical trials: B-cell Malignancy
Leukemia, Lymphocytic, Chronic, B-Cell
DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia
Phase 2 study to assess the efficacy of INVAC-1, a DNA plasmid encoding a modified human telomerase reverse transcriptas (hTERT) protein, at a dose of 800 µg for 6 cycles 4 weeks apart on Minimal Residual Disease (MRD)…
- Trial name
- NCT03265717
- Testing
- INVAC-1
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Invectys
B-cell Non-Hodgkin's Lymphoma (B-NHL)
Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
The main objective of this study is to observe and evaluate the safety and tolerability of the XP-006 personalized tumor mRNA vaccine for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
- Trial name
- XP-006 (NCT07334574)
- Testing
- Personalized neoantigen tumor vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Lymphoma
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290706
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Chronic Lymphocytic Leukemia
An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia
This study will examine the effectiveness of MabThera therapy added to a standard chemotherapy regimen for the treatment of previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02080884
- Where
- 15 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
B-Cell Non-Hodgkin Lymphoma
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- NCT05201248
- Testing
- Epcoritamab, Cyclophosphamide, Rituximab
- Where
- 18 sites in China
- Volunteers
- 49 people
- Sponsor
- Genmab
Chronic Lymphocytic Leukemia
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
This is a multicentre single-arm prospective phase II trial evaluating pirtobrutinib in the treatment of relapsed/refractory (R/R) Chronic Lymphocytic Leukaemia (CLL) patients who have previously received zanubrutinib, and to…
- Trial name
- PIPOZA (NCT06812715)
- Testing
- Pirtobrutinib
- Where
- 3 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lymphoma, Large B-Cell, Diffuse
Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression
DLBCL has the highest frequency out of all lymphoid malignancies. With the recent development of antitumor agents targeting intracellular/extracellular cell signaling pathways, patients have access to various treatment options…
- Trial name
- COGET-B (NCT03977623)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Leukemia
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
The goal of the clinical research study is to find the highest tolerable dose of nelarabine when given as a continuous infusion to patients with a lymphoid malignancy that has not responded to, or has come back after treatment…
- Trial name
- NCT01094860
- Testing
- Nelarabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus Lenalidomide (Revlimid®) to induce objective responses in patients with Mucosa Associated Lymphoid Tissue (MALT) lymphoma presenting…
- Trial name
- NCT01611259
- Testing
- Rituximab and Lenalidomide
- Where
- 5 sites in Austria
- Volunteers
- 50 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
B-cell Malignancy
Phase I Study of HRS-3005 in B-cell Malignancies
The study is being conducted to evaluate the safety and tolerability of HRS-3005. To explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D).
- Trial name
- NCT07556822
- Testing
- HRS-3005
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
B-cell Tumors
A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects
This study used a single-dose, open and fixed sequence design to compare the pharmacokinetics in healthy subjects.
- Trial name
- NCT05560360
- Testing
- SHR1459 tablet, Efavirenz tablet
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION
Chronic lymphocytic leukemia (CLL) is a highly heterogeneous B-cell hematological malignancy characterized by clonal expansion and accumulation of morphologically mature B-lymphocytes with a peculiar immunophenotype in peripheral…
- Trial name
- LLC/LEF1 2024 (NCT07313982)
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
RATIONALE: Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and the best dose of carfilzomib in treating patients…
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT01212380
- Testing
- carfilzomib, Cytokine Assessment, Pharmacodynamic Studies
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
FT819 in Subjects With B-cell Malignancies
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia.
- Conditions
- Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
- Trial name
- NCT04629729
- Testing
- FT819, Cyclophosphamide, Fludarabine
- Where
- 18 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fate Therapeutics
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
- Trial name
- NCT00055653
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- 25 sites in United States
- Sponsor
- Roswell Park Cancer Institute
Lymphoma, Relapsed Lymphoma
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
This is a phase 1, open-label, dose-escalation study of fimepinostat (CUDC-907) in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2…
- Conditions
- Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma
- Trial name
- NCT01742988
- Testing
- fimepinostat, Rituximab, venetoclax
- Where
- 11 sites in United States
- Volunteers
- 106 people
- Sponsor
- Curis, Inc.
Diffuse Large B-Cell Lymphoma
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
This study evaluates the feasibility and safety of bridging radiation therapy, including a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with…
- Trial name
- HyDEF (NCT06898905)
- Testing
- Bridging Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
The main purpose of this study is to test the safety and efficacy of VS-4718 in two types of leukemia patients and to find the right dose of VS-4718 for future clinical trials.
- Trial name
- NCT02215629
- Testing
- VS-4718
- Sponsor
- Verastem, Inc.
Follicular Lymphoma, Diffuse Large Cell Lymphoma
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.
- Conditions
- Follicular Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT00275431
- Testing
- AT-101
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- Ascenta Therapeutics